Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study

Mario Chojkier, Hisham Elkhayat, Dina Sabry, Michael Donohue, Martina Buck, Mario Chojkier, Hisham Elkhayat, Dina Sabry, Michael Donohue, Martina Buck

Abstract

Background: Insulin resistance (IR) is induced by chronic hepatitis C virus (HCV) genotypes 1 and 4 infections. It is not known whether drugs that affect IR such as Pioglitazone and Prednisone also affect serum HCV RNA titers independently of PEG-Interferon-α2/ribavirin treatment. The primary aim was to assess whether Pioglitazone by improving IR and/or inflammation decreases HCV viral load independently of standard of care HCV treatment. A secondary aim was to assess whether Prednisone, a drug that induces insulin resistance and stimulates HCV viral entry and replication in replicon culture systems, increases HCV viral load in this population.

Methodology/principal findings: We designed a two-arm, parallel Pilot Study of overweight, treatment naïve genotype 4 HCV-infected patients at a public referral Liver Clinic in Giza, Egypt. The subjects received Pioglitazone (30 mg/day for 14 days) or Prednisone (40 mg/day for 4 days) in a randomized fashion, but the two arms can be considered independent pilot studies. Only changes from baseline within each arm were assessed and no contrasts of the interventions were made, as this was not an aim of the study. Among 105 consecutive HCV genotype 4 patients, 39 were enrolled based on the optimal sample size and power analysis according to the CONSORT statement; 20 to the Pioglitazone group and 19 to the Prednisone group. Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0.001). Although Prednisone did increase serum HCV RNA at day-4 (n = 10; change from baseline = -42,786 IU/ml; 95% CI -85,500 to -15,700; P = 0.049), the log(10) HCV RNA titers were statistically not different from baseline day-0.

Conclusion/significance: This is the first documentation that Pioglitazone decreases the serum HCV RNA titers independently of PEG-Interferon-α2/ribavirin treatment. The novel findings of our Study provide the foundation for basic and clinical investigations on the molecular mechanisms responsible for the Pioglitazone-induced decrease in HCV genotype 4 RNA titers.

Trial registration: ClinicalTrials.gov NCT01157975.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Participant Flow.
Figure 1. Participant Flow.
Patients with chronic Hepatitis C genotype 4 referred to the Hepatology Clinic were assessed for eligibility as described in Methods.

References

    1. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, et al. Hepatitis C Virus Infection and Incidence Type 2 Diabetes. Hepatology. 2003;38:50–56. 10.1053/jhep.2003.50291.
    1. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. Journal of Hepatology. 2008;49:831–844. 10.1016/j.jhep.2008.08.006.
    1. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134:416–423.
    1. Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, et al. Changes in Insulin Sensitivity and Body Weight During and After Peginterferon and Ribavirin Therapy for Hepatitis C. Gastroenterology. 2011;140:469–477.
    1. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636–641.
    1. Torres DM, Harrison SA. Insulin resistance in chronic hepatitis C, genotypes 1 and 4: the unfortunate reality. Hepatology. 2008;47:2137–2139.
    1. Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. American Journal of Gastroenterology. 2010;105:1970–1977.
    1. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, et al. Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance. New England Journal of Medicine. 2011;364:1104–1115. 10.1056/NEJMoa1010949.
    1. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2010;362:1675–1685. 10.1056/NEJMoa0907929.
    1. Overbeck K, Genne D, Golay A, Negro F Swiss Association for the Study of the Liver (SASL) Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. Journal of Hepatology. 2008;49:295–298.
    1. Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver International. 2010;30:447–454.
    1. Willi SM, Kennedy A, Wallace P, Ganaway E, Rogers NL, et al. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes. 2002;51:2895–2902.
    1. Ciesek S, Steinmann E, Iken M, Ott M, Helfritz FA, et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology. 2010;138:1875–1884.
    1. Herzberg-Schafer SA, Staiger H, Heni M, Ketterer C, Guthoff M, et al. Evaluation of fasting state-/oral glucose tolerance test-derived measures of insulin release for the detection of genetically impaired ß-cell function. PLOS One. 2010;5:e14194.
    1. Wagoner J, Austin M, Green J, Imaizumi T, Casola A, et al. Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during Hepatitis C virus infection. Journal of Virology. 2007;81:309–318.
    1. Zeuzem S. Interferon-based therapy for chronic Hepatitis C: current and future perspectives. Nature Clinical Practice Gastroenterology & hepatology. 2008;5:610–622.
    1. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with Type 2 Diabetes Mellitus. A meta-analysis of randomized trials. JAMA. 2007;298:1180–1188. 10.1001/jama.298.10.1180.
    1. Yokoo H, Kondo T, Fujii K, Yamada T, Todo S, et al. Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology. 2004;40:609–617.
    1. Vondracek SF, Hemstreet BA. Is there an optimal corticosteroid regimen for the management of an acute exacerbation of chronic obstructive pulmonary disease? Pharmacotherapy. 2006;26:522–532.
    1. Schulz KF, Altman DG, Moher D for the CONSORT Group. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med. 2010;7:e1000251. 10.1371/journal.pmed.1000251.
    1. Nguyen TT, Sedghi-Vaziri A, Wilkes LB, Mondala T, Pockros PJ, et al. Fluctations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. Journal of Viral Hepatitis. 1996;3:75–78. 10.1111/j.1365-2893.1996.tb00084.x.
    1. Harrison SA, Hamzeh F, Han J, Vierling JM. Efficacy, Safety, and Metabolic Effects in Chronic Hepatitis C (CHC) Genotype 1 (G1) Patients With Insulin Resistance (IR) Treated With Pioglitazone (PIO) and Peginterferon Alfa-2a Plus Ribavirin (P/R). Hepatology. 2011;54:439.
    1. Conjeevaram H, Burant CF, McKenna B, Harsh D, Kang H, et al. A randomized, double-blind, placebo-controlled study of ppar-gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. Hepatology. 2008;48:384.
    1. Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology. 2006;43:1168. 10.1002/hep.21125.
    1. Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, et al. Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology. 2009;Dec;50(6):1702–8.
    1. Serfaty L, Fartoux L, Poupon R. Pioglitazone as adjuvant therapy in chronic hepatitis C: Sequential rather than concomitant administration with pegylated interferon and ribavirin? Journal of Hepatology. 2009;50:1269–1271. 10.1016/j.jhep.2009.02.014.
    1. Dharancy S, Lemoine M, Mathurin P, Serfaty L, Dubuquoy L. Peroxisome Proliferator- Activated Receptors in HCV-Related Infection. PPAR Res. 2009:357204. doi: .
    1. Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Study of effectiveness of bezafibrate in the treatment of chronic hepatitis C. The American Journal of Gastroenterology. 2001;96:1659–1660.
    1. Fujita N, Kaito M, Tanaka H, Horiike S, Adachi Y. Reduction of serum HCV RNA titer by bezafibrate therapy in patients with chronic hepatitis C. The American Journal of Gastroenterology. 2004;99:2280.
    1. Olefsky JM, Glass CK. Macrophages, inflammation and insulin resistance. Annual Review of Physiology. 2010;72:219–246.
    1. Galli A, Crabb DW, Ceni E, Salzano R, Svegliati-Baroni G, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 2002;122:1924–1940.
    1. Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, et al. Arginase-1-Expressing Macrophages Suppress Th2 Cytokine-Driven Inflammation and Fibrosis. PLoS Pathog. 2009;5:e1000371. 10.1371/journal.ppat.1000371.
    1. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest. 2005;115:56–65.
    1. Polyak SJ, Khabar KSA, Rezeiq M, Gretch DR. Elevated Levels of Interleukin-8 in Serum Are Associated with Hepatitis C Virus Infection and Resistance to Interferon Therapy. Journal of Virology. 2001;75:6209–6211. 10.1128/JVI.75.13.6209-6211.2001.
    1. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–802. 10.1038/nature08463.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다